Coya Therapeutics' COYA 303 Demonstrates Anti-Inflammatory Effects in Preclinical Alzheimer's Model
Key Insights
Coya Therapeutics' COYA 303 (search), a combination of low-dose IL-2 and GLP-1 receptor agonist (search), showed significant anti-inflammatory effects in brain regions and enhanced regulatory T cell function in a preclinical mouse model.
The investigational therapy demonstrated attenuation of neuroinflammation in cortex and hippocampus regions while reducing pro-inflammatory myeloid cells and associated cytokines compared to untreated animals.
Results support COYA 303 (search)'s potential for treating Alzheimer's disease (search) and other neurodegenerative conditions driven by chronic inflammation, with additional cohorts underway to optimize treatment protocols.
Coya Therapeutics has announced promising preclinical results for COYA 303 (search), an investigational biologic combination therapy designed to combat neuroinflammation in Alzheimer's disease (search) and other neurodegenerative conditions. The therapy demonstrated significant anti-inflammatory effects in both the central nervous system and peripheral immune system in a validated mouse model of systemic and neuroinflammation.
Dual-Target Approach Shows Promise
COYA 303 (search) combines low-dose interleukin-2 (LD IL-2) with a GLP-1 receptor agonist (search) (GLP-1RA) for subcutaneous administration. The therapy targets two key pathways implicated in neurodegeneration: enhancing regulatory T cell (Treg) function and modulating myeloid cell activity.
In the first cohort of an in vivo lipopolysaccharide (LPS) mouse model study, COYA 303 (search) demonstrated broad immunomodulatory activity. The treatment significantly reduced LPS-induced pro-inflammatory myeloid cells and associated cytokines while increasing anti-inflammatory immune cell subsets. Most notably, the therapy attenuated neuroinflammation in critical brain regions including the cortex and hippocampus.
"We are encouraged by the positive signal in Cohort 1," stated Dr. Arun Swaminathan, Coya's Chief Executive Officer. "These data are particularly timely given the increasing recognition of GLP-1 receptor agonists as potential therapies beyond metabolic disease."
Mechanism of Action
The therapeutic approach leverages the complementary mechanisms of its two components. LD IL-2 preferentially binds the IL-2 receptor alpha (search), which is highly expressed on Tregs and plays a key role in enhancing their anti-inflammatory function. Treg dysfunction is implicated in autoimmune and neurodegenerative diseases characterized by persistent inflammation.
GLP-1 receptor agonists also modulate immune responses, with both myeloid cells and Tregs expressing high densities of GLP-1 receptors (search). Previous in vitro studies conducted by Coya showed that combining LD IL-2 with a GLP-1RA synergistically enhances Treg numbers and function while reducing pro-inflammatory activity.
Key Study Findings
The preclinical study revealed several significant outcomes:
COYA 303 (search) significantly enhanced Treg numbers and suppressive function, addressing a key dysfunction underlying neurodegenerative diseases. The therapy also reduced peripheral activated myeloid cells, which contribute to systemic inflammation that can exacerbate neurodegeneration.
In the central nervous system, COYA 303 (search) demonstrated significant attenuation of neuroinflammation in both cortex and hippocampus brain regions, areas critical for cognitive function that are affected in Alzheimer's disease (search).
The results confirm previously reported positive findings from in vitro human immune cell systems, demonstrating that COYA 303 (search) significantly enhances Treg suppressive function and survival in highly inflammatory microenvironments.
Broader Implications for Neurodegeneration
The findings support Coya's broader research into inflammation's role in neurodegenerative diseases. The company has sponsored research demonstrating the potentially critical role of inflammation in the progression and severity of conditions including amyotrophic lateral sclerosis (search) (ALS), frontotemporal dementia (search) (FTD), and Alzheimer's disease (search).
A separate study published in Frontiers of Immunology, partially funded by Coya and led by scientific advisors, explored immune dysfunction in Parkinson's disease (search) pathogenesis. The research demonstrated correlations between peripheral pro-inflammatory mechanisms, particularly monocytes and oxidative stress, in disease progression and severity.
Next Steps
Experimental cohorts 2 and 3 are currently underway, designed to assess modified treatment protocols and evaluate the impact of treatment initiation timing relative to inflammation onset. Upon completion of the full dataset, Coya intends to present and publish the findings in a peer-reviewed forum.
The company believes these findings illustrate COYA 303 (search)'s potential to modulate inflammatory pathways implicated in Alzheimer's disease (search) progression and support continued development in neurodegenerative conditions where persistent inflammation drives pathology.
Swaminathan noted the timing significance: "The upcoming semaglutide readout in Alzheimer's Disease (search) has generated strong interest, and we believe our unique approach of combining LD IL-2 with a GLP-1RA in COYA 303 (search) may leverage both Treg enhancement and myeloid modulation to address the systemic and neuroinflammatory drivers of neurodegeneration."